SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* Knight Jeff E. (Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD (Street) SAN DIEGO CALIFORNIA 92121 (City) (State) (Zip) UNITED STATES (Country)	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [ CRNX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Dev. & Operating Officer
	2a. Foreign Trading Symbol
	3. Date of Earliest Transaction (Month/Day/Year) 04/08/2026	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		M		49,474	A	$23.98	161,492	D
Common Stock	04/08/2026		M		9,624	A	$20.02	171,116	D
Common Stock	04/08/2026		M		19,336	A	$19.64	190,452	D
Common Stock	04/08/2026		S(1)		85,163	D	$40.1(2)	105,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.98	04/08/2026		M			49,474	(3)	09/01/2031	Common Stock	49,474	$0	63,027	D
Stock Option (Right to Buy)	$20.02	04/08/2026		M			9,624	(4)	02/29/2032	Common Stock	9,624	$0	10,589	D
Stock Option (Right to Buy)	$19.64	04/08/2026		M			19,336	(5)	03/01/2033	Common Stock	19,336	$0	65,977	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments.

4. 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022.

5. The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)